FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis

  • The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was healthy.
  • FDA issues warning on possible false results from noninvasive prenatal screening tests.
  • The agency noted that these tests, also known as noninvasive prenatal tests (NIPT), have not been approved. 
  • They are designed only to tell the risk of the fetus having certain genetic abnormalities. Diagnostics tests are needed to confirm or deny a suspected abnormality.
  • The FDA said it is aware of reports of women who ended pregnancies following a genetic prenatal test.
  • The FDA said it is aware of cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy.
  • Companies offering NIPS/NIPT screenings include Natera Inc NTRAInvitae Corp NVTAMyriad Genetics Inc MYGNAgilent Technologies Inc APerkinElmer Inc PKIIllumina Inc ILMN, and Roche Holdings AG RHHBY.
Loading...
Loading...
NTRA Logo
NTRANatera Inc
$160.990.56%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
93.74
Growth
85.83
Quality
-
Value
15.93
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...